DOCSLIB.ORG

EMJ-5.2-2020-4.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
EMJ-5.2-2020-4.Pdf Contents + EDITORIAL BOARD 4 + CONGRESS REVIEW Review of the European Conference on Rare Diseases, 10 15th – 16th May 2020 + FEATURE The COVID-19 Conundrum and Cancer – Making Perfect Sense of 19 Imperfect Data Utkarsh Acharya + SYMPOSIUM REVIEW Early Intervention with Anti-Tumour Necrosis Factor in Ulcerative 22 Colitis: The Missing Piece of The Puzzle? + POSTER REVIEWS Eicosapentaenoic Acid: Atheroprotective Properties and the Reduction 29 of Atherosclerotic Cardiovascular Disease Events Chlormethine Gel for Mycosis Fungoides T-cell Lymphoma: Recent 37 Real-World Data + INTERVIEWS Data from the AUGUSTUS Trial Adds an Important Piece to the 42 Complex Puzzle of Antithrombotic Treatment for Those with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention Renato D. Lopes and Amit N. Vora Oral Prostacyclin Pathway Agents in Pulmonary Arterial Hypertension: 47 An Expert Clinical Consensus Vallerie McLaughlin and Sean Gaine 2 EMJ • June 2020 • Cover Image © Anna Grigorjeva / 123rf.com EMJ “It is more important than ever that information is disseminated rapidly and responsibly in the face of such global threats” Spencer Gore, CEO + ARTICLES Editor's Pick: Bone-Related Markers of Cardiovascular Disease 54 Ernesto Maddaloni et al. National Institute for Health and Care Excellence (NICE) Guidelines on 63 Cannabis-Based Medicinal Products: Clinical Practice Implications for Epilepsy Management Rhys H. Thomas and Jacob Brolly The Role of Next-Generation Sequencing and Reduced Time to 76 Diagnosis In Haematological Diseases: Status Quo and Prospective Overview of Promising Molecular Testing Approaches Christina Ranft Bernasconi et al. Sebaceous Carcinoma: A Rare Extraocular Presentation of the Cheek 85 Ritu Swali et al. Pathophysiology Underpinning Gestational Diabetes Mellitus and the 90 Role of Biomarkers for its Prediction Natassia Rodrigo & Sarah J. Glastras Case Report: Inhaled Nitroglycerine as an Alternative to Inhaled 97 Nitric Oxide in the Acute Treatment of Pulmonary Hypertension and Impending Acute Right Ventricular Failure in the Intensive Care Unit Khaled Sorour et al. A Case Report: Isolated Pontine Lesion in Hypertensive of a Pregnant 103 Patient with Idiopathic Thrombocytopeni Ilknur Yardimci et al. Mesenteric Panniculitis in a patient with Homozygous Factor V Leiden 108 gene mutation: A Case and Literature to Review. Mohammad Sohaib Asghar et al. Breast Cancer Immunotherapy: From Biology to Current Clinical 113 Applications Jorge Henrique Santos Leal and Heather McArthur Managing Pemphigoid Gestationis 125 Christine Sävervall and Simon Francis Thomsen + WHAT'S NEW 136 Creative Commons Attribution-Non Commercial 4.0 June 2020 • EMJ 3 Editorial Board Editor-in-Chief Prof Markus Peck-Radosavljevic Klinikum Klagenfurt am Wörthersee, Austria Editorial Board Dr Pierfrancesco Agostoni St. Antonius Hospital, Netherlands Dr Fernando Alfonso Hospital Universitario de La Princesa, Spain Dr Emanuele Angelucci IRCCS Ospedale Policlinico, San Martino, Italy Dr George Anifandis University of Thessaly, Greece Dr Riccardo Autorino Virginia Commonwealth University, USA Prof Ahmad Awada Jules Bordet Institute, Belgium Dr Sorin T. Barbu “Iuliu Hațieganu” University of Medicine & Pharmacy, Romania Dr Mátyás Benyó University of Debrecen, Hungary Prof Andrew Bush Imperial College London, UK Dr Abdullah Erdem Canda Yildirim Beyazit University, Turkey Dr Ian Chikanza Barts and The Royal London Hospital, UK Dr Hassan Galadari United Arab Emirates University, United Arab Emirates Prof Jörg Huber University of Brighton, UK Prof Norbert Lameire Ghent University, Belgium Dr Amir Hamzah Abdul Latiff Pantai Hospital, Malaysia Dr Lorenz Räber Bern University Hospital, Switzerland Prof Lászlo Vécsei University of Szeged, Hungary VIEW IN FULL 4 EMJ • June 2020 EMJ Aims and Scope We are always keen to hear from healthcare professionals wishing to discuss potential submissions, please email: EMJ is an online only, peer-reviewed, open access general journal, targeted towards readers in the medical sciences. [email protected] We aim to make all our articles accessible to readers from To submit a paper, use our online submission site: any medical discipline. www.editorialmanager.com/e-m-j EMJ allows healthcare professionals to stay abreast of key advances and opinions across Europe. Submission details can be found through our website: www.emjreviews.com/contributors/authors EMJ aims to support healthcare professionals in continuously developing their knowledge, effectiveness, Reprints and productivity. The editorial policy is designed to encourage discussion among this peer group. All articles included in EMJ are available as reprints (minimum order 1,000). Please contact EMJ is published quarterly and comprises review articles, [email protected] if you would like to order reprints. case reports, practice guides, theoretical discussions, and original research. Distribution and Readership EMJ also publishes 18 therapeutic area journals, which provide concise coverage of salient developments at EMJ is distributed through controlled circulation to the leading European congresses. These are published healthcare professionals in the relevant fields annually, approximately 6 weeks after the relevant across Europe. congress. Further details can be found on our website: www.emjreviews.com Indexing and Availability Editorial Expertise EMJ is indexed on DOAJ, the Royal Society of Medicine, and Google Scholar®; selected articles are indexed in EMJ is supported by various levels of expertise: PubMed Central®. • Guidance from an Editorial Board consisting of leading EMJ is available through the websites of our leading authorities from a wide variety of disciplines. partners and collaborating societies. • Invited contributors are recognised authorities from their respective fields. EMJ journals are all available via our website: www.emjreviews.com • Peer review, which is conducted by EMJ’s Peer Review Panel as well as other experts appointed due to their knowledge of a specific topic. Open Access • An experienced team of editors and technical editors. This is an open-access journal in accordance with the Creative Commons Attribution-Non Commercial 4.0 Peer Review (CC BY-NC 4.0) license. On submission, all articles are assessed by the editorial team to determine their suitability for the journal and Congress Notice appropriateness for peer review. Staff members attend medical congresses as reporters Editorial staff, following consultation with either a when required. member of the Editorial Board or the author(s) if necessary, identify three appropriate reviewers, who are This Publication selected based on their specialist knowledge in the relevant area. European Medical Journal is published four times a year. For subscription details please visit: All peer review is double blind. www.emjreviews.com Following review, papers are either accepted without ISSN 2397-6764 modification, returned to the author(s) to incorporate required changes, or rejected. All information obtained by EMJ and each of the contributions from various sources is as current and Editorial staff have final discretion over any proposed amendments. accurate as possible. However, due to human or mechanical errors, EMJ and the contributors cannot guarantee the accuracy, adequacy, or completeness of Submissions any information, and cannot be held responsible for any We welcome contributions from professionals, errors or omissions. consultants, academics, and industry leaders on relevant and topical subjects. Front cover and contents photograph: Stockholm, Sweden. © Anna Grigorjeva / 123rf.com We seek papers with the most current, interesting, and relevant information in each therapeutic area and accept original research, review articles, case reports, and features. Creative Commons Attribution-Non Commercial 4.0 June 2020 • EMJ 5 EMJ 5.2 Chief Executive Officer Operations Assistants Spencer Gore Satkartar Chagger, Emma Knight Senior Project Director Daniel Healy Editor Evgenia Koutsouki Chief Operating Officer Dan Scott Deputy Managing Editor Sam Davis Head of Publishing Hamish Dickie Content Manager Kirstie Turner Head of Content Marketing Sen Boyaci Editorial Assistants Lenos Archer-Diaby, Michaila Byrne, Katherine Head of Commercial Colvin, Rachel Donnison, Anaya Malik, Isabel Michael McConaghy O’Brien, Layla Southcombe Performance Managers Editorial Consultant Darren Brace, Magnus Barber, Robert Hancox Katie Earl Senior Project Managers Design Manager Hayley Cooper, Nabihah Durrani, Stacey Rivers Millie McGowan, Max Roy Graphic Designers Project Managers Roy Ikoroha, Warren Uytenbogaardt Lucy Bull, Emilie De Meritens, Tilly Flack, Rhian Frost, Mary Gregory, Rebecca Harrison, Jessica Junior Designer Lowman, Lewis Mackie, Thomas Madden, Emma Rayner Billy Nicholson, Fabian Niavarany, Alexsander Director of Digital Innovation Popovic, Alexander Skedd, Caleb Wright, Fiona Salmon Mariana Napoleao Digital and Data Innovation Manager Sales Administrator Louis Jonesco Simi Ige Marketing Assistant Head of Client Services Noah Banienuba Courtney Jones Head of Finance Executive Assistant Nikki Curtis Emma Cook Head of Recruitment Head of Operations Karen Lee Keith Moule 6 EMJ • June 2020 EMJ Welcome It is my great pleasure to introduce the newest edition of our flagship journal EMJ 5.2. The pages inside contain the latest exciting developments from a wide range of therapeutic areas. As the COVID-19 pandemic continues to dominate the headlines
Load more

Recommended publications
  • Clinical Pharmacology in the UK, C. 1950–2000: Industry and Regulation
    CLINICAL PHARMACOLOGY IN THE UK, c. 1950–2000: INDUSTRY AND REGULATION The transcript of a Witness Seminar held by the Wellcome Trust Centre for the History of Medicine at UCL, London, on 25 September 2007 Edited by L A Reynolds and E M Tansey Volume 34 2008 ©The Trustee of the Wellcome Trust, London, 2008 First published by the Wellcome Trust Centre for the History of Medicine at UCL, 2008 The Wellcome Trust Centre for the History of Medicine at UCL is funded by the Wellcome Trust, which is a registered charity, no. 210183. ISBN 978 085484 118 9 All volumes are freely available online at: www.history.qmul.ac.uk/research/modbiomed/wellcome_witnesses/ Please cite as: Reynolds L A, Tansey E M. (eds) (2008) Clinical Pharmacology in the UK c.1950-2000: Industry and regulation. Wellcome Witnesses to Twentieth Century Medicine, vol. 34. London: Wellcome Trust Centre for the History of Medicine at UCL. CONTENTS Illustrations and credits v Abbreviations vii Witness Seminars: Meetings and publications; Acknowledgements E M Tansey and L A Reynolds ix Introduction Professor Parveen Kumar xxiii Transcript Edited by L A Reynolds and E M Tansey 1 References 73 Biographical notes 89 Glossary 103 Index 109 ILLUSTRATIONS AND CREDITS Figure 1 AstraZeneca Clinical Trials Unit, South Manchester. Reproduced by permission of AstraZeneca. 6 Figure 2 A summary of the organization of clinical trials. Adapted from www.clinicaltrials.gov/ct2/info/glossary (visited 1 May 2008). 10 Figure 3 Clinical trial certificates (CTC) and clinical trial exemption (CTX), 1972–1985. Adapted from Speirs (1983) and Speirs (1984).
    [Show full text]
  • Wellcome Four Year Phd Programme in Integrative Cell Mechanisms
    2021 Wellcome Four Year PhD Programme in Integrative Cell Mechanisms Training the next generation of Molecular Cell Biologists Background and Aims of Programme The Wellcome Four Year PhD Programme in Integrative Cell Mechanisms (iCM) is closely associated with the Wellcome Centre for Cell Biology and trains the next generation of cell and molecular biologists in the application of quantitative methods to understand the inner workings of distinct cell types in different settings. A detailed understanding of normal cellular function is required to investigate the molecular cause of disease and design future treatments. However, data generated by biological research requires increasingly complex analysis with technological advances in sequencing, mass spectrometry/proteomics, super-resolution microscopy, Wellcome Centre for Cell Biology 2021 synthetic and structural biology generating increasingly large, complex datasets. In addition, innovations in computer sciences and informatics are transforming data acquisition and analysis and breakthroughs in physics, chemistry and engineering allow the development of devices, molecules and instruments that drive the biological data revolution. Exploiting technological advances to transform our understanding of cellular mechanisms will require scientists who have been trained across the distinct disciplines of natural sciences, engineering, informatics and mathematics. To address this training need, iCM PhD projects are cross-disciplinary involving two primary supervisors with complementary expertise. Supervisor partnerships pair quantitative scientists with cell biologists ensuring that students develop pioneering cross-disciplinary collaborative projects to uncover cellular mechanisms relevant to health and disease. We aim to recruit students with a variety of backgrounds across the biological and physical sciences, including Biochemistry, Biomedical Science, Cell Biology, Chemistry, Computational Data Sciences, Engineering, Genetics, Mathematics, Molecular Biology and Physics.
    [Show full text]
  • A Case Study of Glaxosmithkline Plc )
    )l GROWTH THROUGH MERGER: A CASE STUDY OF GLAXOSMITHKLINE PLC ) / BY JUNE WANGARI UNIVERSITY OF NAIR03J LOWER KABETE LIBRARY A MANAGEMENT RESEARCH PROJECT SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE AWARD OF DEGREE OF MASTER OF BUSINESS ADMINISTRATION (MBA), SCHOOL OF BUSINESS, UNIVERSITY OF NAIROBI JULY, 2008 DECLARATION I declare that this project is my original work and has never been presented for academic purposes in any other University. CANDIDATE: JUNE WANGARI DATE .(.91. This research project has been submitted for examination with my approval as the University Supervisor SIGNED. DATE. Prof. Evans Aosa Department Of Business Administration, School Of Business, University Of Nairobi 11 DEDICATION I dedicate this project to my daughter Jemima, who was born within the first year of my post graduate studies. And now that she is in kindergarten, I see that I have instilled in her the love for reading and learning and I trust that she will go very far. iii ACKNOWLEDGEMENT I thank God for seeing me through my studies as I tried to balance between my family, my work and my studies. I wish to acknowledge the contributions that were made in the course of this project by several individuals and organizations. I wish to acknowledge gratefully the following people, whose effort influenced the content and direction of this project. My first thanks go to my Supervisor Prof. Evans Aosa for his constant analytical criticism and encouragement. Thanks a lot. I wish to thank my friends for a lot of support and encouragement to me in pursuit of this goal.
    [Show full text]
  • Drugs That Changed the World
    Drugs That Changed the World Drugs That Changed the World How Therapeutic Agents Shaped Our Lives Irwin W. Sherman CRC Press Taylor & Francis Group 6000 Broken Sound Parkway NW, Suite 300 Boca Raton, FL 33487-2742 © 2017 by Taylor & Francis Group, LLC CRC Press is an imprint of Taylor & Francis Group, an Informa business No claim to original U.S. Government works Printed on acid-free paper Version Date: 20160922 International Standard Book Number-13: 978-1-4987-9649-1 (Hardback) This book contains information obtained from authentic and highly regarded sources. While all reasonable efforts have been made to publish reliable data and information, neither the author[s] nor the publisher can accept any legal respon- sibility or liability for any errors or omissions that may be made. The publishers wish to make clear that any views or opinions expressed in this book by individual editors, authors or contributors are personal to them and do not neces- sarily reflect the views/opinions of the publishers. The information or guidance contained in this book is intended for use by medical, scientific or health-care professionals and is provided strictly as a supplement to the medical or other professional’s own judgement, their knowledge of the patient’s medical history, relevant manufacturer’s instructions and the appropriate best practice guidelines. Because of the rapid advances in medical science, any information or advice on dosages, procedures or diagnoses should be independently verified. The reader is strongly urged to consult the relevant national drug formulary and the drug companies’ and device or material manufacturers’ printed instructions, and their websites, before administering or utilizing any of the drugs, devices or materials mentioned in this book.
    [Show full text]
  • Blunted Endogenous Opioid Release Following an Oral Dexamphetamine Challenge in Abstinent Alcohol- Dependent Individuals
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Explore Bristol Research Turton, S., Myers, J. F. M., Mick, I., Colasanti, A., Venkataraman, A., Durant, C., ... Lingford-Hughes, A. (2018). Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol- dependent individuals. Molecular Psychiatry. https://doi.org/10.1038/s41380-018-0107-4 Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1038/s41380-018-0107-4 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Nature Publishing Group at https://www.nature.com/articles/s41380-018-0107-4 . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms Molecular Psychiatry https://doi.org/10.1038/s41380-018-0107-4 ARTICLE Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol-dependent individuals 1 1 1,2 3,4 1 1 Samuel Turton ● James FM Myers ● Inge Mick ● Alessandro Colasanti ● Ashwin Venkataraman ● Claire Durant ● 5 6 6 7 8,9 8,10 Adam Waldman ● Alan Brailsford ● Mark C Parkin ● Gemma Dawe ● Eugenii A Rabiner ● Roger N Gunn ● 11 1 1 Stafford L Lightman ● David J Nutt ● Anne Lingford-Hughes Received: 21 September 2017 / Revised: 9 May 2018 / Accepted: 14 May 2018 © The Author(s) 2018.
    [Show full text]
  • 260 Book Reviews
    Book Reviews relation to the development of neurology as a arguments of Kant or Goethe, or indeed medical specialty and to knowledge of the Alexander Bain, were not? brain. (This in part perhaps reflects the lack of This “life” will give great pleasure and archival material on Head’s scientific work.) interest to many readers, perhaps most of all In particular, Head’s career as a theorist draws to those who, like Head himself, find both on the work of John Hughlings Jackson, work the sciences and the arts personally which, so Head claimed, had been almost indispensable. totally ignored. Had it? What reception did Head’s theory of sensation have? The Roger Smith, biography does not enable us to judge Head’s Moscow originality. (For Jackson, one should turn, perhaps the message is, to Jacyna’s earlier fine study, Lost words: narratives of language and Roy Church and E M Tansey, Burroughs the brain, 2000.) Head’s functionalist way of Wellcome & Co.: knowledge, trust, profit thinking encouraged him to mix physiological and the transformation of the British and psychological languages and therapies. pharmaceutical industry, 1880–1940, How special was this? Secondly, the book Lancaster, Crucible Books, 2007, pp. xxvii, does look “outwards” from the archive, as 564, illus. £19.99, $39.99 (paperback 97801- opposed to using the archive to illuminate the 905472-07-9). man, in two regards. The first of these, naturally, is to use the individual career to This work, based on detailed research of the illustrate contemporary medical practice. In firm’s archives, aims to tell the history of addition, however, Jacyna proposes a large Burroughs Wellcome, founded by Silas thesis, which gives the book its title, that Burroughs and Henry Wellcome in 1880, Head’s manner of life and work makes him an which eventually became the largest British exemplary “modernist”.
    [Show full text]
  • British Thoracic Society Winter Meeting
    February 2021 Volume 76 Supplement 1 76 S1 Volume 76 Supplement 1 Pages A1–A256 ThoraxAN INTERNATIONAL JOURNAL OF RESPIRATORY MEDICINE British Thoracic Society THORAX Winter Meeting Wednesday 17 to Friday 19 February 2021 Programme and Abstracts February 2021 February thorax.bmj.com PROGRAMME AND Thorax ABSTRACTS British Thoracic Society Winter Meeting Wednesday 17 to Friday 19 February 2021 Programme and Abstracts Approved by the Federation of the Royal Colleges of Physicians of the UK for 18 category I (external) credits (6 credits per day). Code: 133787 DAILY PROGRAMME WEDNESDAY 17 FEBRUARY 2021 All Symposia, Guest Lectures, Journal Clubs and Spoken Sessions will be shown online live at the times below, and will be available to view via the relevant ‘session type’ tab online. Poster presentations will be pre-recorded and available on demand each day and should be viewed prior to the Poster Discussion Q&A, which will be online live at the times below, all via the ‘Poster Sessions’ tab. Time Session Type Session Title 7.00am – 6.00pm Poster viewing on demand P1-P11 Lessons from COVID-19 throughout the day with live P12-P24 Lung cancer: treatment options and care pathways discussions at the programmed P38-P51 COPD: clinical science times P63-P75 Primary care and paediatric asthma P76-P88 Virtually systematic: current interventions and digital delivery in pulmonary rehabilitation 7.45am – 8.00am Symposium Daily preview 8.00am – 8.30am BTS Journal Club New insights to chronic cough 8.30am – 10.00am Symposium Neutrophilic asthma 8.30am –
    [Show full text]
  • 94771408.Pdf
    VSB — TECHNICAL UNIVERSITY OF OSTRAVA FACULTY OF ECONOMICS DEPARTMENT OF FINANCE Zhodnocení finanční pozice společnosti GlaxoSmithKline, a.s. Evaluation of Financial Position of the Company GlaxoSmithKline plc. Student: Xinran Chen Supervisor of the bachelor thesis: Ing. Ingrid Petrová, Ph.D. Ostrava 2017 Content 1 Introduction ......................................................................................................................... 4 2 Description of the Financial Analysis Methodology ........................................................... 6 2.1 Goal of financial analysis ......................................................................................... 6 2.2 Source of data for financial analysis ......................................................................... 7 2.2.1 Balance sheet .................................................................................................. 7 2.2.2 Income statement ............................................................................................ 9 2.2.3 Cash flow statement ..................................................................................... 10 2.3 Common-size analysis ............................................................................................ 12 2.3.1 Vertical common-size analysis ..................................................................... 12 2.3.2 Horizontal common-size analysis ................................................................ 13 2.4 Financial ratio analysis ..........................................................................................
    [Show full text]
  • The History of Ergot Of
    J R Coll Physicians Edinb 2009; 39:365–9 Paper doi:10.4997/JRCPE.2009.416 © 2009 Royal College of Physicians of Edinburgh The history of ergot of rye (Claviceps purpurea) II: 1900–1940 MR Lee Emeritus Professor of Clinical Pharmacology and Therapeutics, University of Edinburgh, Edinburgh, UK ABSTRACT Ergot, in 1900, was a ‘chemical mess’. Henry Wellcome, the Published online December 2009 pharmaceutical manufacturer, invited Henry Hallett Dale, a physiologist, to join his research department and solve this problem. Dale, in turn, recruited an Correspondence to MR Lee, outstanding group of scientists, including George Barger, Arthur Ewins and 112 Polwarth Terrace, Harold Dudley, who would make distinguished contributions not only to the Edinburgh EH11 1NN chemistry of ergot but also to the identification of acetylcholine, histamine and tel. +44 (0)131 337 7386 tyramine and to studies on their physiological effects. Initially Barger and Dale isolated the compound ergotoxine, but this proved to be a false lead; it was later shown to be a mixture of three different ergot alkaloids. The major success of the Wellcome group was the discovery and isolation of ergometrine, which would prove to be life-saving in postpartum haemorrhage. In 1917 Arthur Stoll and his colleagues started work on ergot at Sandoz Pharmaceuticals in Basel. A series of important results emerged over the next 30 years, including the isolation of ergotamine in 1918, an effective treatment for migraine with aura. KEYWORDS Henry Dale, ergometrine, ergotamine, ergotoxine, migraine, postpartum haemorrhage DECLaratION OF INTERESTS No conflict of interests declared. In 1904, at the age of 29, Henry Hallett Dale joined the Burroughs Wellcome Research Laboratory in London (Figure 1).
    [Show full text]
  • The World's Health Care Crisis
    The World’s Health Care Crisis This page intentionally left blank The World’s Health Care Crisis From the Laboratory Bench to the Patient’s Bedside By Ibis Sánchez-Serrano AMSTERDAM • BOSTON • HEIDELBERG • LONDON • NEW YORK • OXFORD PARIS • SAN DIEGO • SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Elsevier 32 Jamestown Road, London, NW1 7BY 225 Wyman Street, Waltham, MA 02451, USA First edition 2011 Copyright © 2011 Elsevier Inc. All rights reserved No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the Publisher. Details on how to seek permission, further information about the Publisher’s permissions policies and our arrangement with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein). Notices Knowledge and best practice in this field are changing constantly. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary. Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods, they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility. To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.
    [Show full text]
  • Exosomes: a Source of Novel Disease Biomarkers in Bladder Cancer
    Exosomes: A source of novel disease biomarkers in bladder cancer Joanne Louise Welton BSc (Hons), MPhil Thesis presented for the degree of Philosophiae Doctor July 2010 Section of Oncology and Palliative Medicine School of Medicine Velindre Cancer Centre Whitchurch Cardiff CF15 2TL UMI Number: U514248 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. Dissertation Publishing UMI U514248 Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author. Microform Edition © ProQuest LLC. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 DECLARATION This work has not previously been accepted in substance for any degree and is not concurrently submitted in candidature for any degree. Signed ... .................................................................. (candidate) Date STATEMENT 1 This thesis is being submitted in partial fulfillment of the requirements for the degree of PhD Signed ...................................................... (candidate) Date .!2%/05?\/2,QV.O STATEMENT 2 This thesis is the result of my own independent work/investigation, except where otherwise stated. Other sources are acknowledged by explicit references. Signed ....................................................... (candidate) Date STATEMENT 3 I hereby give consent for my thesis, if accepted, to be available for photocopying and for inter- library loan, and for the title and summary to be made available to outside organisations.
    [Show full text]
  • Sir Henry Wellcome's Museum for the Science of History
    Medical History, 1986, 30: 383-418. SIR HENRY WELLCOME'S MUSEUM FOR THE SCIENCE OF HISTORY by GHISLAINE M. SKINNER* "The study of anthropology comprehends all human activities including the healing art"' The collection of artefacts amassed by Sir Henry Solomon Wellcome (1853-1936) known, since 1913, as his Historical Medical Museum and, since its transfer to the Science Museum in 1977, as the Wellcome Museum of the History of Medicine, has frequently aroused amazement because of its enormous size and range. By the early 1930s, Wellcome's collection was five times larger than that ofthe Louvre and, during the 1920s, its annual expenditure on acquisitions exceeded that of the British Museum.2 Despite being known as a historical medical collection, in range it was almost indefinably wide. At the time of Wellcome's death, it included large quantities of, for example, weapons, model ships, bales of fabric, furniture, porcelain, statuary, coins and medals, oriental and western antiquities, objets d'art, potsherds, human remains and "ethnographical" items, in all approximately one million objects.3 This paper is an attempt to place Wellcome's activities in context. His collection becomes more comprehensible when considered in the light of the prominence museums were given in archaeology and anthropology from about 1870, and the * Ghislaine M. Skinner, MB, BS, MSc, Wellcome Museum of the History of Medicine, The Science Museum, South Kensington, London SW7 2DD. I Henry Wellcome, in Great Britain, Royal Commission on nationalmuseums andgalleries, 'Oralevidence, memoranda and appendices to the fial report, London, HMSO, 1929, p. 10. Hereinafter Evidence. 2 In 1933, the Louvre held 173,000 items.
    [Show full text]